Loading...
OTCM
SEELQ
Market cap0kUSD
Mar 28, Last price  
0.00USD
1Q
-99.77%
Name

Seelos Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
116.63%
Rev. gr., 5y
-71.98%
Revenues
2m
359,3692,399,1611,866,9271,270,3675,957,4912,973,7084,972,7374,101,1248,416,0002,511,0009,259,0004,839,0005,763,00000375,0000002,203,000
Net income
-38m
L-50.25%
-17,023,648-15,442,438-8,043,253-8,787,228-5,171,198-32,042,562-29,508,346-18,117,198-31,771,000-16,938,000-21,786,000-19,023,000-7,433,000321,000-9,242,000-50,383,000-19,220,000-67,533,000-76,138,000-37,882,000
CFO
-24m
L-61.18%
-15,227,782-9,835,721-6,667,014-6,587,633-2,712,451-3,514,649-6,889,033-9,724,898-14,395,000-15,065,000-18,015,000-22,642,000-13,068,000-10,466,000-8,129,000-19,305,000-20,913,000-48,995,000-61,604,000-23,912,000
Earnings
May 12, 2025

Profile

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
URL
https://seelostherapeutics.com/
IPO date
Oct 27, 1993
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,203
 
Cost of revenue
72,762
70,969
Unusual Expense (Income)
NOPBT
(70,559)
(70,969)
NOPBT Margin
Operating Taxes
2,604
Tax Rate
NOPAT
(70,559)
(73,573)
Net income
(37,882)
-50.25%
(76,138)
12.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
18,919
1,486
BB yield
Debt
Debt current
14,228
11,923
Long-term debt
15
8,272
Deferred revenue
Other long-term liabilities
Net debt
11,247
4,662
Cash flow
Cash from operating activities
(23,912)
(61,604)
CAPEX
Cash from investing activities
Cash from financing activities
11,375
(1,597)
FCF
(51,205)
(73,606)
Balance
Cash
2,996
15,533
Long term investments
Excess cash
2,886
15,533
Stockholders' equity
(252,616)
(214,637)
Invested Capital
233,334
224,148
ROIC
ROCE
365.93%
EV
Common stock shares outstanding
4,900
3,545
Price
Market cap
EV
EBITDA
(70,502)
(70,916)
EV/EBITDA
Interest
75
14
Interest/NOPBT